Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic γδT Cells for MDR-TB
NCT03575299Phase 1Unknown
- Start
- Jun 2018
- Primary completion
- Jun 2021
- Modality
- Prophylactic Vaccines, Cell Therapies, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of allogeneic gamma-delta T cells in pulmonary tuberculosis (TB) (2 arms). Primary endpoint: Sputum smear conversion rate at 6 months. Status: unknown.
02
Drugs
allogeneic gamma-delta T cells
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on NCT03575299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03575299.